Scott Gottlieb takes a turn in the spotlight for FDA candidates; Triumphant Achaogen lines up stock sale
Reuters has stumbled on to the news that Scott Gottlieb is under consideration by the Trump team for new chief of the FDA. Most of the rest of the biopharma world, though, was well aware that the Republican stalwart would factor in as a top candidate for this position, which he has been prepping for throughout the Obama administration’s 8-year term. The recent brouhaha over reports that Peter Thiel associate Jim O’Neill – who has expressed some radical ideas on approving new drugs on safety data alone – may well have helped Gottlieb’s position as the more acceptable figure for the post.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
